Market Newsdesk

HERZLIYA, Israel, May 20, 2021 /PRNewswire/ — Nayax Ltd. (TASE: NYAX) announced today that it will release its financial results for the first quarter of 2021 on Thursday, May 27, 2021.

Yair Nechmad, Chief Executive Officer, David Ben-Avi, Chief Technology Officer and Liron Grosman, Chief Financial Officer will host a conference call to review the Company’s financial results on the same day, at 8:30 a.m. Eastern Time/ 3:30 p.m. Israel Time.

To attend the conference call, please dial one of the following teleconferencing numbers. Please begin by placing your call at least five minutes before the conference call commences. If you are unable to connect using the toll-free numbers, please try the international dial-in number.

U.S. TOLL-FREE: 1-866-777-2509
ISRAEL TOLL-FREE: 1-80-9212373
INTERNATIONAL: 1-412-317-5413
AUSTRALIA TOLL-FREE: 1-800-822-994
WEBCAST LINK: https://services.choruscall.com/mediaframe/webcast.html?webcastid=epGRwS05 

At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time
3:30 p.m. Israel Time

The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10156749/e8b8fa53af. Callers will receive a unique dial-in upon registration, which enables immediate access on the day of the call. Participants may pre-register at any time, including up to and after the call start time.

The conference call will also be available via live webcast from a link on Nayax’s Investor Relations website.

A replay of the conference call will be available from May 28, 2021, to June 10, 2021. To access the replay, please dial one of the following numbers: 

Replay TOLL-FREE: 1-877-344-7529
Replay TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 10156749

An archived and live media frame will also be available for 90 days on Nayax’s Investor Relations website.

ABOUT NAYAX
Nayax is a global commerce enablement and payments platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and consumer engagement tools, enabling merchants to conduct commerce anywhere, at any time. With foundations and global leadership in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers’ growth across channels. Today, Nayax has 10 global offices, over 400 employees, connections to more than 80 merchant acquirer and payment method integrations and is a recognized payment facilitator worldwide. Nayax’s mission is to improve our customers’ revenue potential and operational efficiency

Visit www.nayax.com for more information.

The securities referred to in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or under the securities laws of any state of the United States, and may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. In the United States, any offer of the ordinary shares will be made only to “qualified institutional buyers” as defined in and in reliance on Rule 144A under the Securities Act or another available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Outside the United States, any offer will be made in accordance with Regulation S of the Securities Act.

Forward looking statement

The information included in this press release contains, or may be deemed to contain, forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995 and the Israeli Securities Law, 1968). Said forward-looking statements, relating to the initial public offering, are subject to uncertainties and assumptions and the actual results may materially differ. All forward-looking statements in this press release are based on information available to Nayax on the date hereof.  All written or oral forward-looking statements attributable to Nayax are expressly qualified in their entirety by the factors referred to above. Nayax does not intend to update these forward-looking statements.

Investor Relations Contact:
Miri Segal
MS-IR LLC
[email protected]
Tel: +1-917-6078654

View original content:http://www.prnewswire.com/news-releases/nayax-to-report-first-quarter-2021-financial-results-on-may-27-2021-301295817.html

SOURCE Nayax

VANCOUVER, BC, May 20, 2021 /PRNewswire/ – Fosterville South Exploration Ltd. (“Fosterville South”) or (the “Company”) (TSXV: FSX) (OTC: FSXLF) (Germany: 4TU) is pleased to report the results of a soil sampling program at Enoch’s Point goldfield (Walhalla Gold Belt Project) and Reedy Creek goldfield (Providence Gold Project) that has detected five significant As-Sb epizonal anomalies.  Soil sampling and assaying in the areas are ongoing.

Epizonal gold mineralised systems have arsenic-antimony mineralisation haloes that are used as trace element pathfinders, such that the larger the halo then the larger the potential gold mineralization.

Based on the location of some of these anomalies, the Company has been recently active in the area strategically expanding the footprint of the land package and through its wholly owned subsidiary Currawong Resources, has increased the size of its Walhalla Gold Belt Project by filing two additional tenement applications totalling 218km². These new tenement applications border the Enoch’s Point, Harbinger and Pinnacles tenements. The company now holds contiguous tenements and tenement applications covering approximately 72km of strike in the western and central parts of the Walhalla Gold Belt.

 Enoch’s Point

The Enoch’s Point project covers 290km² of highly prospective ground within the Woods Point – Walhalla Gold Belt, with numerous gold prospects.  The latest soil sampling program has generated three extensive As±Sb epizonal anomalies within this area:

• The Dray Track arsenic anomaly that is approximately 1 km by 1 km.
• The Big River Sb prospect to Hope Track anomaly that is approximately 3.2 km by 600 m
• The Londonderry Reef that is approximately 1.6 km in length and up to 100 m wide.

Dray Track Prospect.  The Big River Sb Prospect is hosted by Siluro-Devonian folded and faulted sediments and occurs near the Eildon Thrust Fault, which is west bounding structure of the Enoch’s Point Thrust Fault Zone. Reconnaissance regional soil sampling traverses discovered an pXRF arsenic anomalous zone outlining an area approximately 1km in diameter, with some outcrops of pyritic quartz stockwork veining in sandstone.  Gold assays for these soil samples are pending.

Big River Sb Prospect to Hope Track.  The Big River Sb Prospect is hosted by Siluro-Devonian folded and faulted sediments and occurs in close proximity to the Jerusalem Inlet Fault, which is part of the Enoch’s Point Thrust Fault Zone. This fault zone extends for tens of kilometers north to south across the entire state of Victoria. A soil program was conducted at the Big River Antimony Mine, which has outlined an area of As-Sb pXRF soil anomalism covering strike length of 1km by 600m width and possibly extending 1.6km south to the Hope Track arsenic anomalous traverse, as well as north to another ridge traverse making an overall strike extent of 3.2km and up to 600m wide.  Mineralisation is therefore open along strike in both north and south directions beyond these two remote traverses. Fosterville South is exploring the intervening ground currently to establish mineralisation continuity. Gold assays for these soil samples are pending.

Londonderry Reef.  The Londonderry gold prospect is hosted by the Devonian Norton Gully Sandstone and historic gold production is from mineralised quartz stockwork sandstone and diorite dykes. Grid based sampling results determined that anomalous arsenic soil samples occur for a 1.6 km strike length and remains open north and south.  Previous rock chip results had reported grades of up to 179 g/t Au (see Fosterville South News Release March 17, 2021).

Wild Dog Ring Dyke.  The Wild Dog Ring Dyke consists of granite and almandine-bearing granodiorite porphyry. This porphyry contains antimony-gold in sheeted quartz chlorite and carbonate veins, with sericite alteration haloes. Within the Enoch’s Point licence, the dyke extends for 23km and is variably Au-As-Sb mineralised for its entire length. BHP drilled two holes in the south in 1985 and CRAE drilled two holes in the central part in 1994. All holes are less than 136m depth. Previous explorers soil sampling traverses indicate numerous gold mineralised prospects occur which require follow up in this very prospective structure. 

Reedy Creek

The Reedy Creek goldfield forms part of the Providence Project in the Melbourne Zone of Central Victoria west of the Walhalla Gold Belt. The goldfield is hosted by the Silurian Dargile Formation of siltstone and sandstone set in a northwest striking doubly plunging anticlinal dome. This geological setting is similar to the Costerfield dome which is being mined by Mandalay Resources and is currently one of the highest-grade gold mines in the world. The Reedy Creek goldfield is well known for its high-grade historic gold production. This goldfield that has never been previously explored or drilled by modern techniques. Soil sampling has generated various areas of mineralisation and exploration is ongoing, both as infill sampling and in the neighbouring landowner properties. The latest sampling program has identified two extensive As-Sb epizonal anomalies:

• The Prince of Wales Reef and satellite mineralisation extends 1.6 km by 440 m.
• Big Ben prospect area soil anomalies extend over the entire 2km grid.

Prince of Wales Reef.  A north-northwest striking pXRF arsenic anomalous trend is present and associated with the 600m long Prince of Wales reef, which was worked by several gold mining companies in the late 1800s. Further east there is a parallel arsenic trend that shows quartz veining.  This secondary area of potential mineralization has had no historical mining. The soil geochemical anomalies are open along strike in both directions and landowner access is being or has been secured. Historic gold workings extend for a further 2.5km southeast of the soil grid and 3km northwest of the soil grid on various mined structures within the overall corridor.

Big Ben Prospect.  The Big Ben prospect area is hosted by Devonian Humevale Siltstone and occurs partly within the contact metamorphic aureole of the Mount Robertson granodiorite intrusion. Various Au-As mineralised structures occur within the prospect including those associated with the Harry’s Dyke and Big Ben gold workings. The main continuous Au-As anomaly lies in the southwest of the grid and is at least 600m in strike length and up to 120m wide. Soil sampling has covered an area of 2000m by 800m and soil sampling is ongoing. Further gold assay results are pending for the newly acquired soil samples.

Rex Motton states “These extensive As-Sb epizonal soil anomalies contain significant strike length and may indicate various robust gold systems through a number of our properties.  Each of Enoch’s Point and Reedy Creek are high-priority target areas for future drilling by FSX”.

Fosterville South is very active in its exploration of a host of its highest value targets in the largest prospective package in Victoria and has now moved into an expanded operations headquarters in Bendigo, Australia. Expanded field teams, drill rigs and geologists are accelerating the activity throughout the tenements. With in excess of $25 million in cash on hand, Fosterville South is in excellent shape to continue this ramp up and expects to report consistent news flow on its activities.

In addition to regional fieldwork, such as described in today’s News Release, the company has ongoing active exploration programs, including drilling at the Lauriston, Moormbool and Golden Mountain projects.

Quality Assurance / Quality Control

All portable XRF arsenic and antimony assays of the collected soil samples are conducted by Currawong Resources staff, which includes regular duplicates, blanks and supplied instrument standards with the expected results from the samples submitted. The quality control results are consistent. Sampling has been done in several campaigns and follow up results have been supportive of previous results.

The gold assays were subject to quality control measures appropriate for reconnaissance rock chip sampling with duplicates, blanks and commercially available standards with the expected results from the samples submitted. All assays were conducted by Onsite Laboratory Services Ltd (ISO: 9001), located in Bendigo, Victoria, using fire assay techniques with a 50g charge and AAS finish. The quality control results are consistent.

About Fosterville South Exploration Ltd.

Fosterville South began with two, 100% owned, high-grade gold projects called the Lauriston and Golden Mountain Projects, and has since acquired a large area of granted and application tenements containing further epizonal (low-temperature) high-grade gold mineralisation called the Providence Project and a large group of recently consolidated license tenement applications called the Walhalla Belt Project, which contain a variety of epizonal and intrusion related style gold mineralisation, all in the state of Victoria, Australia. The Fosterville South land package, assembled over a multi-year period, notably includes a 600 sq. km property immediately to the south of and within the same geological framework that hosts Kirkland Lake Gold’s Fosterville epizonal gold tenements. Additionally, Fosterville South has gold-focused projects called the Moormbool and Beechworth, which are also located in the state of Victoria, Australia. Moormbool project has epizonal style gold mineralisation and Beechworth has mesozonal and intrusion relation gold mineralisation.

All of Fosterville South’s properties, with the possible exception of Moormbool, have had historical gold production from hard rock sources despite limited modern exploration and drilling.

Qualified Person

The technical content of this news release has been reviewed, verified and approved by Rex Motton, AusIMM (CP), COO and Director of Fosterville South, a qualified person as defined by NI 43-101.  Historical records were verified by reviewing annual and quarterly reports from government records by the Qualified Person.

On behalf of the Company
Rex Motton
Chief Operating Officer and Director

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Fosterville South cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by many material factors, many of which are beyond their respective control. Such factors include, among other things: risks and uncertainties relating to Fosterville South’s limited operating history, its exploration and development activities on is Lauriston and Golden Mountain Properties and the need to comply with environmental and governmental regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Fosterville South does not undertake to publicly update or revise forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fosterville-south-expands-walhalla-gold-belt-project-footprint-after-fieldwork-identifies-multiple-as-sb-epizonal-anomalies-301295744.html

SOURCE Fosterville South Exploration Ltd.

WESTMINSTER, Colo., May 20, 2021 /PRNewswire/ — Ball Corporation (NYSE: BLL) today announced that the first-of-its-kind Ball Aluminum Cup™ is now available for purchase at major retailers in all 50 states across the U.S. Between May and June, the cups will be available for the first time in more than 18,000 food, drug and mass retailers, including Kroger, Target, Albertsons, CVS and others.

“Ball has a long history of being a brand that people trust, and we are excited to reenter the B2C market with the retail rollout of the innovative and infinitely recyclable Ball Aluminum Cup™,” said Dan Fisher, President. “As a company, we are relentlessly focused on enabling the circular economy and finding new ways to help solve the packaging waste crisis with aluminum beverage packaging. We look forward to working with our retail partners to continue advancing this mission.”   

“The Ball Aluminum Cup™ is a truly innovative product that has the potential to advance sustainability and reduce plastic waste at gatherings big and small,” said Sebastian Siethoff, General Manager, Cups. “As we expand the cups’ availability to major retailers nationwide, we are seeing very strong consumer adoption and performance in the marketplace as we are launching this new, exciting product line. We are excited to expand the cups’ footprint and continue driving meaningful sustainable solutions for customers and consumers.”  

The nationwide retail rollout follows the success of a limited pilot that began in 2019. Since then, the cups have been available in select retailers, restaurants, and major sports and entertainment venues such as Ball Arena in Denver, SoFi Stadium in Inglewood and Allegiant Stadium in Las Vegas. The cups are also available on Amazon, where they are currently the #3 best-selling product in the cups category.

Ball, a leader in cutting-edge aluminum beverage packaging, as well as climate monitoring and weather forecasting technologies through the Ball Aerospace business, has made sustainability foundational to its business, operations and products. Ball developed the aluminum cup over the past several years in response to growing customer and consumer demand for sustainability. It is designed to be used at home and in other areas where disposable plastic cups are common, including indoor and outdoor venues across the country.

Infinitely recyclable and economically valuable, aluminum is the most sustainable beverage packaging material and, like aluminum cans, aluminum cups can be easily recycled. Globally, 75 percent of the aluminum ever produced is still in use today. In addition to its sustainability and recycling strengths, the aluminum cup is lightweight, sturdy, and cool to the touch, and it can be customized with logos and graphics.

Ball is producing the cups domestically from its dedicated cups manufacturing facility in Rome, Ga. The product is available in 20-ounce and 16-ounce formats.

Ball worked with Seed Strategy, a Burke Inc. innovation and brand strategy consultancy, on the national advertising campaign for the retail rollout. In addition, Ball is represented in the national marketplace by Acosta Sales & Marketing.    

For more information, please visit www.ball.com/cups.

About Ball Corporation
Ball Corporation supplies innovative, sustainable aluminum packaging solutions for beverage, personal care and household products customers, as well as aerospace and other technologies and services primarily for the U.S. government. Ball Corporation and its subsidiaries employ 21,500 people worldwide and reported 2020 net sales of $11.8 billion. For more information, visit www.ball.com, or connect with us on Facebook or Twitter.

Forward-Looking Statements
This release contains “forward-looking” statements concerning future events and financial performance. Words such as “expects,” “anticipates,” “estimates,” “believes,” and similar expressions typically identify forward-looking statements, which are generally any statements other than statements of historical fact. Such statements are based on current expectations or views of the future and are subject to risks and uncertainties, which could cause actual results or events to differ materially from those expressed or implied. You should therefore not place undue reliance upon any forward-looking statements and any such statements should be read in conjunction with, and qualified in their entirety by, the cautionary statements referenced below. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Key factors, risks and uncertainties that could cause actual outcomes and results to be different are summarized in filings with the Securities and Exchange Commission, including Exhibit 99 in our Form 10-K, which are available on our website and at www.sec.gov. Additional factors that might affect: a) our packaging segments include product capacity, supply, and demand constraints and fluctuations and changes in consumption patterns; availability/cost of raw materials, equipment, and logistics; competitive packaging, pricing and substitution; changes in climate and weather; footprint adjustments and other manufacturing changes, including the startup of new facilities and lines; failure to achieve synergies, productivity improvements or cost reductions; unfavorable mandatory deposit or packaging laws; customer and supplier consolidation; power and supply chain interruptions; changes in major customer or supplier contracts or loss of a major customer or supplier; political instability and sanctions; currency controls; changes in foreign exchange or tax rates; and tariffs, trade actions, or other governmental actions, including business restrictions and shelter-in-place orders in any country or jurisdiction affecting goods produced by us or in our supply chain, including imported raw materials; b) our aerospace segment include funding, authorization, availability and returns of government and commercial contracts; and delays, extensions and technical uncertainties affecting segment contracts; c) the Company as a whole include those listed above plus: the extent to which sustainability-related opportunities arise and can be capitalized upon; changes in senior management, succession, and the ability to attract and retain skilled labor; regulatory action or issues including tax, environmental, health and workplace safety, including U.S. FDA and other actions or public concerns affecting products filled in our containers, or chemicals or substances used in raw materials or in the manufacturing process; technological developments and innovations; the ability to manage cyber threats; litigation; strikes; disease; pandemic; labor cost changes; rates of return on assets of the Company’s defined benefit retirement plans; pension changes; uncertainties surrounding geopolitical events and governmental policies both in the U.S. and in other countries, including policies, orders, and actions related to COVID-19; reduced cash flow; interest rates affecting our debt; and successful or unsuccessful joint ventures, acquisitions and divestitures, and their effects on our operating results and business generally.

 

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ball-corporation-brings-ball-aluminum-cup-to-major-retailers-in-all-50-states-301295742.html

SOURCE Ball Corporation

SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The data will be featured in an upcoming electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.

The newly announced data are from a phase 2 trial evaluating pelareorep in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®) in pancreatic adenocarcinoma patients who progressed after first-line treatment. Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in these difficult-to-treat patients, which is mediated through the complementary immunotherapeutic effects of the two agents.

“These results are very promising, particularly considering the extremely challenging patient population enrolled in the trial. That we saw a response signal in select patients, despite the absence of chemotherapy, provides evidence of the considerable anti-cancer activity of pelareorep-pembrolizumab combination therapy,” said Principal Investigator, Devalingam Mahalingam, M.D., Ph.D., Associate Professor of Medicine at The Northwestern University Feinberg School of Medicine and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “We notably observed an association between treatment-induced anti-cancer immune responses and improved tumor control in some patients, which demonstrates pelareorep’s underlying immunologic mechanism of action and validates the strategy of combining it with checkpoint inhibition. I look forward to discussing these data with the scientific community at the upcoming ASCO conference and to the continued evaluation of pelareorep-checkpoint inhibitor combination therapy in select patients with pancreatic and other gastrointestinal cancers.”

The data presented in the upcoming ASCO poster represent an update based on additional data that was collected after the cutoff date used for the poster’s corresponding abstract. Key data and conclusions that will be featured in this upcoming poster include:

• Disease control was achieved in 42% (5/12) of patients, with one patient achieving a partial response and four patients achieving stable disease
• On-treatment tumor biopsies showed pelareorep replication and increased infiltration of CD8+ T cells and PD-L1+ cells relative to pre-treatment samples
• Patients achieving disease control showed reductions in pro-tumor regulatory T (T­_reg) cells in the peripheral blood and tumor tissue compared to those with progressive disease
• Patients achieving disease control showed increased activation of anti-cancer CD8+ T cells in the peripheral blood compared to those with progressive disease
• Pelareorep-pembrolizumab combination therapy was found to be well tolerated, with most treatment-related adverse events being grade 1 or 2

Bin Zhang, M.D., Ph.D., Professor at The Northwestern University Feinberg School of Medicine, commented, “These data show that pelareorep can train the immune system to target pancreatic cancer while simultaneously promoting the infiltration of T cells into the tumor and remodeling the tumor microenvironments (TMEs) to be less immunosuppressive. This positions pelareorep to synergistically combine with both checkpoint inhibitors as well as a broad range of other immuno-oncology agents.”

“The findings from this study highlight the broad applicability of pelareorep’s immunotherapeutic mechanism of action as they are consistent with what has been seen in clinical trials in other indications such as breast cancer,” added Thomas Heineman, M.D., Ph.D., Global Head of Clinical Development and Operations at Oncolytics. “The compelling findings from this phase 2 study highlight the potential of pelareorep to address the critical unmet need in pancreatic cancer by reversing the immunosuppressive TMEs that often limit the efficacy of checkpoint inhibitors. The anti-cancer activity demonstrated in this study bodes well for a successful outcome in our GOBLET trial, which includes a cohort evaluating pelareorep and the PD-L1 inhibitor atezolizumab in combination with chemotherapy as first-line therapy in metastatic pancreatic cancer patients.”

The electronic poster, titled, “Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma” will be made available on the ASCO Annual Meeting website at 9:00 a.m. ET on June 4, 2021. A copy of the poster will also be posted on the Posters & Publications page of Oncolytics’ website (LINK).

Oncolytics plans to further develop pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer in collaboration with Roche and AIO-Studien-gGmbH (AIO) through the GOBLET study, a phase 1/2 multi-center trial designed to investigate the use of pelareorep in combination with Roche’s anti-PD-L1 inhibitor atezolizumab (Tecentriq®) in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers (link to the GOBLET announcement PR). Oncolytics expects the first patient to be dosed in GOBLET in mid-2021. 

About GOBLET

The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication biomarker, safety, and efficacy study in advanced or metastatic GI tumors. The study will be conducted at 25 centers in Germany. The primary endpoint of the study is safety, with overall response rate and biomarker evaluation (T cell clonality and CEACAM6) as exploratory endpoints. Approximately 55 patients are planned for enrollment across four separate cohorts:

1. Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1^st line metastatic pancreatic cancer patients (n=12);
2. Pelareorep in combination with atezolizumab in 2^nd and 3^rd line metastatic colorectal cancer patients that are diagnosed as MSI (microsatellite instability) high (n=19);
3. Pelareorep in combination with atezolizumab and TAS-102 in 3^rd line metastatic colorectal cancer patients (n=14); and
4. Pelareorep in combination with atezolizumab in 2^nd line advanced and unresectable anal cancer patients (n=10).

About Gastrointestinal Cancer

Excluding skin cancers, colorectal cancer is the third most common cancer, with an estimated 104,610 new cases of colon cancer and 43,340 new cases of rectal cancer diagnosed in the U.S. in 2020¹. Also, for the 2020 year, the American Cancer Society estimates there will be 57,600 new cases of pancreatic cancer² and 8,590 new cases of anal cancer ³ in the U.S.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

References:

1.  “Key Statistics for Colorectal Cancer.” The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html

2.  “Key Statistics for Pancreatic Cancer.” The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html

3.  “Key Statistics for Anal Cancer.” The American Cancer Society, American Cancer Society, Inc., https://www.cancer.org/cancer/anal-cancer/about/what-is-key-statistics.html

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding Oncolytics’ belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics’ expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; the timing and anticipated content of the presentation of additional data to be given at the 2021 ASCO annual meeting; our plans to further develop pelareorep through collaborations; the anticipated timing of the first patient being dosed under our GOBLET-1 study; and other statements related to anticipated developments in Oncolytics’ business and technologies.  In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics’ ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.  Investors should consult Oncolytics’ quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

 

 

View original content:http://www.prnewswire.com/news-releases/oncolytics-biotech-announces-clinical-and-biomarker-data-demonstrating-clinical-proof-of-concept-for-pelareorep-checkpoint-inhibitor-combination-in-pancreatic-cancer-301295729.html

SOURCE Oncolytics Biotech® Inc.

WOODLAND PARK, N.J., May 20, 2021 /PRNewswire/ — Anterix (NASDAQ: ATEX), a leading provider of 900 MHz broadband spectrum, announced today it will host a virtual Investor Day on Wednesday, June 16, 2021 beginning at 10:00 a.m. Eastern time.

The presentation will feature a review of the company’s strategic growth in enabling private broadband networks on its 900 MHz spectrum for critical infrastructure and enterprise businesses. The company will also provide its outlook and a general business update for fiscal year 2022 during the presentation. Speakers include:

• Rob Schwartz, President and Chief Executive Officer
• Ryan Gerbrandt, Chief Operating Officer
• Tim Gray, Chief Financial Officer

The presentation and subsequent question and answer session will be webcast on June 16, 2021 beginning at 10 a.m. Eastern time. A link to the webcast will be available on the investor relations section of the Anterix website. A replay of the webcast will also be available on the company’s website. The company will release its fourth quarter and fiscal year end results for the period ended March 31, 2021 on June 15, 2021. To register for the Anterix 2021 Investor Day, please visit the event webpage.

About Anterix
At Anterix, we are focused on delivering transformative broadband that enables the modernization of critical infrastructure for the energy, transportation, logistics and other sectors of our economy. As the largest holder of licensed spectrum in the 900 MHz band, with nationwide coverage throughout the contiguous United States, Hawaii, Alaska and Puerto Rico, we are uniquely positioned to enable the private LTE broadband solutions that support secure, resilient and customer-controlled operations. 

Contacts

Natasha Vecchiarelli 
Director, Investor Relations & Corporate Communications
Anterix
973-531-4397
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/anterix-to-hold-virtual-investor-day-and-discuss-fiscal-2021-fourth-quarter-results-on-june-16-301295734.html

SOURCE Anterix Inc.

Newly created role will leverage Martha’s expertise across the Company’s portfolio of brands

SMITHS FALLS, ON and NEW YORK, May 20, 2021 /PRNewswire/ – Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, CBD and vaporization device company announced the appointment of Martha Stewart as the company’s official strategic advisor. In this new role, Martha will expand upon her existing relationship with the company, leveraging her vast knowledge of product development and branding expertise, to provide the company with dedicated counsel ranging from product innovation to format development and strategic partnerships.

Martha’s appointment comes on the heels of the successful launch of Martha Stewart CBD in partnership with Marquee Brands and Canopy Growth. Launched in Fall 2020, the product line offers high-quality, CBD wellness supplements including gummies, softgels, and oil drops with flavor profiles inspired by some of Martha’s most popular recipes. Martha Stewart CBD for Pet also launched earlier this year and includes oil drops and soft-baked chews in three gourmet flavor combinations and formulas designed to support pet mental and physical well-being.

Since launch, the product line-up has extended into top-selling gift boxes for occasions including Mother’s Day and Valentine’s Day, which sold out prior to the holiday due to high consumer demand. As mainstream awareness for CBD continues to increase, coupled with Martha’s legacy as a trusted source for living well, the product line will continue to serve as a key area of growth for the business.

“Canopy Growth is committed to providing consumers with trusted CBD products with quality ingredients, and Martha Stewart has been a champion of our commitment since the inception of our partnership,” said David Klein, Chief Executive Officer of Canopy Growth. “We are thrilled to deepen our relationship with Martha through this new advisory role. With her expansive business acumen and years of experience with the Canopy team, together we’ll unleash the power of CBD to improve lives and create an unparalleled portfolio of brands.”

Martha will play a pivotal role in shaping Canopy’s product innovation pipeline through her counsel in the development of novel concepts, formats, flavors and strategic alliances. From the curation of new Martha Stewart branded products to curating products for Canopy’s wider portfolio of brands, Martha’s advisory role will help shape the future of the company’s product development trajectory. 

“Over the past year, demand and awareness for CBD products has skyrocketed. Working with the top researchers and scientists at Canopy Growth, I saw first-hand how dedicated the company is in producing high quality, safe and consistent products,” said Martha Stewart. “Deepening my relationship with the business is a natural fit given our aligned dedication and passion for bringing consumers innovative and quality CBD products and I’m thrilled to share the benefits of CBD with consumers all over the country.”

As momentum for the brand continues and demand for the Martha Stewart CBD product portfolio grows, Canopy Growth has also signed a distribution deal with Southern Glazer’s Wine and Spirits, the world’s pre-eminent distributor of beverage alcohol, as the select distributor for Martha Stewart CBD across the U.S. market. The distribution deal follows the recent announcement with Southern Glazer’s and Canopy Growth to distribute Quatreau, Canopy’s first line of CBD-infused beverages sold in the U.S. market. Southern Glazer’s will initially distribute Martha Stewart CBD across seven states, with additional states in the months to come.

About Canopy Growth Corporation
Canopy Growth (TSX: WEED) (NASDAQ: CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, soft gel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its color-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com.

About Marquee Brands:
Marquee Brands is a leading global brand owner and marketer. Owned by investor funds managed by Neuberger Berman, one of the world’s leading employee-owned investment managers, Marquee Brands targets high quality brands with strong consumer awareness and long-term growth potential. Marquee Brands seeks to identify brands in various consumer product segments with the goal of expanding their reach across retail channel, geography and product category while preserving the brand heritage and enhancing the ultimate consumer experience. Through its global team of professionals and partners, Marquee Brands monitors trends and markets in order to grow and manage brands in partnership with retailers, licensees and manufacturers through engaging, impactful strategic planning, marketing, and e-commerce. www.marqueebrands.com. In 2019, Marquee Brands acquired the Martha Stewart brand, which reaches approximately 100 million consumers across all media and merchandising platforms each month. Martha Stewart is the Founder of Martha Stewart Living Omnimedia and America’s most trusted lifestyle expert and teacher. Her branded products can be found in over 70 million households and have a growing retail presence in thousands of locations.

View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-welcomes-martha-stewart-as-official-strategic-advisor-301295741.html

SOURCE Canopy Growth Corporation

TEL AVIV, Israel and RALEIGH, N.C., May 20, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its first quarter 2021 financial results and operational highlights on Thursday, May 27, 2021.

The Company will host a webcast on Thursday, May 27, 2021, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2021.

The webcast including slides will be broadcast live on the Company’s website, https://ir.redhillbio.com/events, and will be available for replay for 30 days.  

To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: United States: +1-877-870-9135; International: +1-646-741-3167 and Israel:
+972-3-530-8845; the access code for the call is: 8506238.

About RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik^® for opioid-induced constipation in adults^[1], Talicia^®for the treatment of Helicobacter pylori (H. pylori) infection in adults^[2], and Aemcolo^® for the treatment of travelers’ diarrhea in adults^[3]. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva^®, ABC294640), a first–in–class SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (v) RHB-102(Bekinda^®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB–106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia^®; (v) the Company’s ability to successfully commercialize and promote Talicia^®, and Aemcolo^® and Movantik^®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2021. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

 

 

[1] Full prescribing information for Movantik^® (naloxegol) is available at: www.Movantik.com.  

[2] Full prescribing information for Talicia^® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.       

[3] Full prescribing information for Aemcolo^® (rifamycin) is available at: www.Aemcolo.com.

 

View original content:http://www.prnewswire.com/news-releases/redhill-biopharma-to-host-first-quarter-2021-financial-results-and-operational-highlights-webcast-on-may-27-2021-301295769.html

SOURCE RedHill Biopharma Ltd.

CHICAGO, May 20, 2021 /PRNewswire/ — Gogo Inc. (NASDAQ: GOGO), the world’s largest provider of broadband connectivity services for the business aviation market, today announced that Oakleigh Thorne, Chairman and CEO of Gogo, will participate in the following three virtual financial conferences:

J.P. Morgan 49^th Annual Global Technology, Media and Communications Conference

Virtual Fireside Chat will occur from 3:40 p.m.-4:15 p.m. EDT on Tuesday May 25, 2021.

William Blair 41^st Annual Growth Stock Conference

Virtual Fireside Chat will occur from 1:40 p.m.-2:10 p.m. EDT on Wednesday June 2, 2021.

Cowen 49th Annual Technology, Media & Telecom Conference

Virtual Fireside Chat will occur from 4:30p.m.-5:00 p.m. EDT on Thursday June 3, 2021.

The Company will be available for investor calls at all three financial conferences. Please contact your respective salesperson for further details.

About Gogo
Gogo is the world’s largest provider of broadband connectivity services for the business aviation market. We offer a customizable suite of smart cabin systems for highly integrated connectivity, inflight entertainment and voice solutions. Gogo’s products and services are installed on thousands of business aircraft of all sizes and mission types from turboprops to the largest global jets, and are utilized by the largest fractional ownership operators, charter operators, corporate flight departments and individuals.

As of March 31, 2021, Gogo reported 1,900 business aircraft flying with Gogo’s AVANCE L5 or L3 system installed, 5,892 aircraft flying with its ATG systems onboard, and 4,614 aircraft with satellite connectivity installed. Connect with us at business.gogoair.com.

 

 

View original content:http://www.prnewswire.com/news-releases/gogo-inc-to-participate-in-upcoming-financial-conferences-301295746.html

SOURCE Gogo Inc.

DUBLIN, May 20, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Emily Peterson Alva, to the company’s Board of Directors (“Board”). Emily Peterson Alva is an experienced public company board member and a financial, strategic and business advisor to growth companies. A former Lazard M&A Partner with more than 15 years of investment banking experience, Ms. Alva brings significant experience navigating complex strategic, transactional and governance matters for public companies across many sectors including specific expertise in healthcare and pharmaceuticals.

“I am delighted to welcome Emily to Alkermes’ Board of Directors and look forward to her insights and perspectives as we focus our efforts on high return-on-investment opportunities that are consistent with our long-term growth strategy,” said Richard Pops, Chief Executive Officer and Chairman of Alkermes.  “As the fifth new independent director appointed to Alkermes’ Board in the last two years, Emily’s addition to the Board underscores our commitment to board diversity, strong corporate governance and meaningful board refreshment.”

“I am pleased to join Alkermes’ Board of Directors at this exciting time and look forward to working closely with other Board members and with management as Alkermes works to make a meaningful impact on the lives of patients and drive value creation for shareholders,” said Ms. Alva.

“Elliott strongly supports Emily’s appointment to the Alkermes Board and its newly formed Financial Operating Committee,” said an Elliott Advisors spokesperson. “Emily brings significant financial and strategic expertise to the Board. This is another welcome step by Alkermes to drive value creation for shareholders as the company implements its Value Enhancement Plan and builds on recent operational progress.”

About Emily Peterson Alva

Emily Peterson Alva is an experienced public and private company board member and an accomplished finance and strategy advisor to founders and leadership teams of growth companies. Ms. Alva has more than two decades of experience leading transactions and strategic evaluations for boards and leadership teams of large global companies and growth companies.  Ms. Alva’s professional experience includes more than 15 years as an investment banker at Lazard, most recently as an M&A Partner. During her Lazard tenure, Ms. Alva advised corporate boards and leadership teams on corporate strategy initiatives. Ms. Alva serves on the Boards of Directors of Amneal Pharmaceuticals, Inc., a global pharmaceutical company, and the Atlanta Life Insurance Company, a financial services company that helps consumers, businesses and communities build and protect wealth. Ms. Alva also serves on the Board of Directors of the Mission Society of New York City. Ms. Alva is a corporate board partner with the Nasdaq Center for Board Excellence and a member of PathNorth, the NextGen Board Leaders, the EY Audit Committee Leaders and Extraordinary Women on Boards; she was also previously selected for the Council on Foreign Relations’ Corporate Leaders Program. Ms. Alva is a faculty member and part of the founding leadership team of the Herndon Directors Institute, an innovative corporate governance initiative focused on the inclusion of business leaders from under-represented communities in corporate board rooms. Ms. Alva received a B.A. in Economics from Barnard College, Columbia University. 

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Important Additional Information

The company has filed a definitive proxy statement, accompanying proxy card and other relevant documents with the Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies for the company’s 2021 annual general meeting of shareholders. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders may obtain a copy of the definitive proxy statement and other documents filed by the company with the SEC free of charge from the SEC’s website at www.sec.gov. In addition, copies will be available at no charge by visiting the “Investors” section of the company’s website at www.alkermes.com.

The company, its directors and certain of its executive officers are considered participants in the solicitation of proxies from shareholders in respect of the company’s 2021 annual general meeting of shareholders. Information regarding the names of such participants and their respective interests in the company by security holdings or otherwise is set forth in the company’s definitive proxy statement for the company’s 2021 annual general meeting of shareholders, filed with the SEC on May 10, 2021, and in Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the company’s focus on high return-on-investment opportunities consistent with its long-term growth strategy and its ability to drive value creation for shareholders; and the potential therapeutic and commercial value of the company’s investigational and commercial products and the company’s work to make a meaningful impact on the lives of patients. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties, including those risks and uncertainties described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2020 and in subsequent filings made by the company with the SEC, which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

Alkermes Contacts:

For Investors:  Sandy Coombs +1 781 609 6377
For Media:  Katie Joyce +1 781 249 8927    

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-announces-the-appointment-of-emily-peterson-alva-to-its-board-of-directors-301295526.html

SOURCE Alkermes plc

TEL AVIV, Israel, May 20, 2021 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2021 on Wednesday, May 26, 2021, before the US markets open.

The Company will host a conference call on Wednesday, May 26, 2021 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial +1-866-744-5399 from the U.S. or +972-3-918-0610 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until May 28, 2021; please dial +1-888-295-2634 from the U.S. or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company’s lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem-cell mobilization for autologous bone-marrow transplantation. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA^® and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all rights to Motixafortide), and is currently being studied in combination with LIBTAYO^® and chemotherapy as a first-line PDAC therapy.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company’s website at www.biolinerx.com, where you can review the Company’s SEC filings, press releases, announcements and events.

Contact:

Tim McCarthy

LifeSci Advisors, LLC
+1-212-915-2564
[email protected]

Moran Meir

LifeSci Advisors, LLC
+972-54-476-4945
[email protected]

View original content:http://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2021-results-on-may-26-2021-301295733.html

SOURCE BioLineRx Ltd.